



isw2024.org

Pregnancy-associated Breast Cancer: Impact of Pregnancy on Surgical Adherence

<u>Mao Li Cheng^{1*}</u>, Visalini Sanmugachandran¹, Yee Ling Tan¹ Sadhana Mahamad¹, Anita Baghawi¹,

Abdullah Nor Hisham¹

¹Department of Surgery, Hospital Putrajaya

Introduction

The incidence of pregnancy-associated breast cancer (PABC) has been in an increasing trend because modern women delay childbearing into their third and fourth decade. Even breast cancer therapies have been progressively advancing to improve survival, PABC women have higher risk of death and recurrence. Therefore, the treatment adherence is crucial for the optimal outcome.

Materials and Methods

All newly diagnosed breast cancer from January 1, 2013, to Sept 30, 2023 were reviewed in this singleinstitution study. PABC is defined as newly diagnosed breast cancer during the antenatal period or in the first postpartum year and the surgical adherence is defined as women undergoing surgery within 30 days of tissue diagnosis or post neoadjuvant chemotherapy.

Results

Category	Total patients, n (%)	Time to surgery interval (Days)		Median (IQR)	
	ii (70)	≤ 30	> 30		
No. Patients, n (%)	30	9 (36.0%)	16 (64.0)	79.0 (36.0, 159.0)	
Breast-conserving surgery	3 (10.0)	0	3 (100.0)	117.3 (33.5)*	
Mastectomy	22 (73.3)	9 (40.9)	13 (59.1)	57.0 (28.8,164.3)	
Reconstruction	3 (13.6)	3 (100.0)	0	124.3 (89.7)*	
No reconstruction	19 (86.4)	13 (68.4)	6 (31.6)	52.0 (29.0, 156.0)	
No surgery	5 (16.7)	-	-	-	
*Moon (CD)					

*Mean (SD)


Table 1 Time to Surgery Interval

Category	Frequency (%)	
	n = 30	

Category	Frequency (%) n = 30		
Tumour size (mm) (Median, IQR)	4.8 (3.0,7.0)		
Tumour histology			
IDC	28 (93.3)		
ILC	0		
DCIS	1 (3.3)		
Others	1 (3.3)		
Grading			
1	1 (3.3)		
2	12 (40.0)		
3	12 (40.0)		
NA	5 (16.7)		
Lymphovascular invasion (LVI)			
Yes	13 (43.3)		
Νο			
NA	11 (43.3)		
Molecular classification			
Luminal A	10 (33 3)		

Malay 28 (93.3) Chinese 2 (6.7) Indian 0 Others 0 Gestation week 17.4 (9.5) First trimester 11 (36.7) Second trimester 11 (36.7) Third trimester 5 (16.7) Postpartum 3 (10.0) Family history of breast cancer 7 Yes 11 (36.6) No 19 (63.3) Comorbidity 24 (80.0) Financial reimbursement 7 Yes 14 (46.7) No 16 (53.3) Presenting symptom 30 (100.0) Non-breast lump 0 Duration of symptom (months) 7 (9.8)	Age (Year) (Mean, SD)	34.2 (4.8)	
Chinese 2 (6.7) Indian 0 Others 0 Gestation week 17.4 (9.5) First trimester 11 (36.7) Second trimester 11 (36.7) Second trimester 5 (16.7) Postpartum 3 (10.0) Family history of breast cancer 3 (10.0) Yes 11 (36.6) No 19 (63.3) Comorbidity	Ethnicity		
Indian 0 Others 0 Gestation week 17.4 (9.5) First trimester 11 (36.7) Second trimester 11 (36.7) Second trimester 5 (16.7) Postpartum 3 (10.0) Family history of breast cancer 3 (10.0) Family history of breast cancer 11 (36.6) No 19 (63.3) Comorbidity	Malay		
Others 0 Gestation week 17.4 (9.5) First trimester 11 (36.7) Second trimester 11 (36.7) Third trimester 5 (16.7) Postpartum 3 (10.0) Family history of breast cancer 3 (10.0) Family history of breast cancer 11 (36.6) No 19 (63.3) Comorbidity 4 (80.0) Financial reimbursement 14 (46.7) Yes 14 (46.7) No 16 (53.3) Presenting symptom 30 (100.0) Breast lump 30 (100.0) Non-breast lump 0 Duration of symptom (months) 7 (9.8)	Chinese	2 (6.7)	
Gestation week 17.4 (9.5) First trimester 11 (36.7) Second trimester 11 (36.7) Third trimester 5 (16.7) Postpartum 3 (10.0) Family history of breast cancer 3 (10.0) Family history of breast cancer 11 (36.6) Yes 11 (36.6) No 19 (63.3) Comorbidity 2 Yes 6 (20.0) No 24 (80.0) Financial reimbursement 14 (46.7) Yes 14 (46.7) No 16 (53.3) Presenting symptom 0 Breast lump 00 (100.0) Non-breast lump 0 Duration of symptom (months) 7 (9.8)	Indian	0	
First trimester 11 (36.7) Second trimester 11 (36.7) Third trimester 5 (16.7) Postpartum 3 (10.0) Family history of breast cancer 3 (10.0) Yes 11 (36.6) No 19 (63.3) Comorbidity 6 (20.0) No 24 (80.0) Financial reimbursement 14 (46.7) Yes 14 (46.7) No 16 (53.3) Presenting symptom 30 (100.0) Non-breast lump 0 Duration of symptom (months) 7 (9.8)	Others		
Second trimester 11 (36.7) Third trimester 5 (16.7) Postpartum 3 (10.0) Family history of breast cancer 3 (10.0) Yes 11 (36.6) 3 (10.0) Comorbidity 19 (63.3) 3 Comorbidity 6 (20.0) 3 3 Financial reimbursement 24 (80.0) 3 3 Financial reimbursement 30 (100.0) 30 (100.0) 30 (100.0) 30 (100.0) Breast lump 30 (100.0) 30 (100.0	Gestation week	17.4 (9.5)	
Third trimester 5 (16.7) Postpartum 3 (10.0) Family history of breast cancer 3 (10.0) Yes 11 (36.6) No 19 (63.3) Comorbidity 6 (20.0) No 24 (80.0) Financial reimbursement 74 (46.7) No 16 (53.3) Presenting symptom 30 (100.0) Non-breast lump 0 Duration of symptom (months) 7 (9.8)			
Postpartum3 (10.0)Family history of breast cancerYesYes11 (36.6)No19 (63.3)ComorbidityYesYes6 (20.0)No24 (80.0)Financial reimbursementYesYes14 (46.7)No16 (53.3)Presenting symptom30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)			
Family history of breast cancer 11 (36.6) Yes 11 (36.6) No 19 (63.3) Comorbidity			
Yes 11 (36.6) No 19 (63.3) Comorbidity			3 (10.0)
No19 (63.3)ComorbidityYes6 (20.0)No24 (80.0)Financial reimbursementYes14 (46.7)No16 (53.3)Presenting symptomBreast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)			
Yes6 (20.0)No24 (80.0)Financial reimbursement14 (46.7)Yes14 (46.7)No16 (53.3)Presenting symptom30 (100.0)Breast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)	Yes		
Yes6 (20.0)No24 (80.0)Financial reimbursement14 (46.7)Yes14 (46.7)No16 (53.3)Presenting symptom30 (100.0)Breast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)		19 (63.3)	
No24 (80.0)Financial reimbursementYes14 (46.7)No16 (53.3)Presenting symptom30 (100.0)Breast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)	-		
Financial reimbursementYes14 (46.7)No16 (53.3)Presenting symptom30 (100.0)Breast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)			
Yes14 (46.7)No16 (53.3)Presenting symptom30 (100.0)Breast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)		24 (80.0)	
No16 (53.3)Presenting symptom30 (100.0)Breast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)	Financial reimbursement		
Presenting symptomBreast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)	Yes	14 (46.7)	
Breast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)		16 (53.3)	
Non-breast lump0Duration of symptom (months)7 (9.8)	Presenting symptom		
Duration of symptom (months) 7 (9.8)	Breast lump	30 (100.0)	
	Non-breast lump	0	
	Duration of symptom (months)	7 (9.8)	
	≤ 3		16 (53.3)
> 3 14 (46.7)	> 3		14 (46.7)

Table 2 Clinical Characteristics



Discussion

This study demonstrated low surgical adherence rate, late-stage presentation and high defaulter rate in PABC. This is likely due to the young women commitment to their families and careers. The family history of breast cancer was associated with surgical adherence. This implied breast cancer awareness improved surgical adherence. However, this is a single center study, which has a comprehensive breast service. To our knowledge, this is the first research on surgical adherence among PABC women.

Conclusion

Breast cancer awareness and treatment counselling are crucial to improve the breast health literacy among PABC women. Hence, better breast health literacy, better surgical adherence.

Luminai A 10 (33.3) Luminal B 8 (26.7) HER-2 4 (13.3) **Triple negative** 8 (26.7)

Table 3 Pathological Characteristics

Category	Frequency (%) n = 24			
Mode of delivery				
Spontaneous vaginal birth	7 (29.2)			
Caesarean section	17 (70.8)			
Prelabour		12 (50.0)		
Intrapartum		5 (20.8)		
Duration of Pregnancy				
Preterm	11 (45.8)			
Term (≥37 weeks)	13 (54.2)			
Maternal morbidity				
Yes	0			
No	24 (100.0)			
Perinatal death				
Yes	0			
No	24 (100.0)			
Birthweight percentiles				
<10 th	9 (37.5)			
10 th – 90 th	14 (58.3)			
>90 th	1 (4.2)			

Table 3 Maternal and Perinatal Outcomes

Category	Adherence (%)	Crude odds ratio	95% CI	Adjusted odds ratio*	95% CI
Family history of breast cancer					
No	3 (33.3)		Refe	rence	
Yes	6 (66.7)	8.7	1.3, 56.2	11.5	1.0, 127.8

*Multiple logistic regression - adjusted for age, ethnicity, gestation week, family history, comorbidity, financial reimbursement, duration of symptoms, and tumour size

Table 4 Univariate and Multivariate Analysis of Surgical Adherence

Reference

- Cheng et al. Breast J. 2020 Mar; 26(3): 568-570 1.
- Bleiche et al. JAMAOncol, 2(3):330-339, 2016 2.
 - Srokowski et al. Cancer, 113(1), 22-29, 2008 3.